Several targeted molecules including anti-vascular endothelial growth factor (VEGF) inhibitors, anti-epidermal growth factor receptor (EGFR) antibodies, and mammalian target of rapamycin (mTOR) inhibitors have been tested for recurrent cervical cancers, showing some promising results for certain patient subsets [4]. The gene discussed is EGFR; the disease is cervical carcinoma.